Euan Walpole

Princess Alexandra Hospital — Australia

Medicine · Health Sciences

42h-index10.6kcitations207works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Esophageal Cancer Research and Treatment(31), Gastric Cancer Management and Outcomes(29), Colorectal Cancer Treatments and Studies(25), Global Cancer Incidence and Screening(23), Hepatocellular Carcinoma Treatment and Prognosis(20)

Publications203 total

Immune Checkpoint Inhibitors in Field Cancerization and Keratinocyte Cancer Prevention
JAMA Dermatology·2025· 4 citedOpen Access
Prognostic markers could extend adjuvant immunotherapy to high-risk stage IB/IIA melanoma: A modeling study
JAAD International·2024· 1 citedOpen Access
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).
Journal of Clinical Oncology·2024
Steroid Premedication and Monoclonal Antibody Therapy: Should We Reconsider?
Current Treatment Options in Oncology·2024· 4 citedOpen Access
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs).
Journal of Clinical Oncology·2023
Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy
Nature Communications·2023· 27 citedOpen Access
Abstract OT2-10-05: HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer
Cancer Research·2023· 2 cited
The Q-IMPROvE (Queensland-IMplementation of PRecision Oncology in brEast cancer) pilot study
2023Open Access
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs).
Journal of Clinical Oncology·2023
Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy
Figshare·2023Open Access
HPV status represents dominant trait driving delineation of survival-associated gene co-expression networks in head and neck cancer
Cancer Gene Therapy·2022· 3 citedOpen Access
Development of a key performance indicator for breast cancer in Queensland, Australia
Breast Cancer Research and Treatment·2022· 2 citedOpen Access
280. MULTI-OMIC FEATURES OF OESOPHAGEAL ADENOCARCINOMA PATIENTS PRE-TREATED WITH PREOPERATIVE NEOADJUVANT THERAPY
Diseases of the Esophagus·2022Open Access
204. THE TUMOUR IMMUNE MICROENVIRONMENT IN OESOPHAGEAL ADENOCARCINOMA HAS PROGNOSTIC SIGNIFICANCE
Diseases of the Esophagus·2022
Development of key performance indicator (KPI) for real-time monitoring of treatment of early breast cancer to control socioeconomic and indigenous systemic bias.
Journal of Clinical Oncology·2022· 2 cited
High‐dose chemotherapy for relapsed germ cell tumours: outcomes in low‐volume specialized centres
British Journal of Urology·2022· 8 citedOpen Access
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
BMC Cancer·2022· 2 citedOpen Access
Additional file 2 of Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
Figshare·2022Open Access
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
Annals of Oncology·2021· 15 citedOpen Access
Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A real‐world study
Pharmacoepidemiology and Drug Safety·2021· 3 cited
page 1 of 11Next →

Frequent Co-authors

B. Mark Smithers(14), Jennifer A. Harvey(9), Bryan Burmeister(8), Damien Thomson(7), Bernard Nordlinger(6), Bengt Glimelius(6), Wolf O. Bechstein(6), Thomas Gruenberger(6), Val Gebski(6), Stephen P. Ackland(6), D. C. Gotley(6), Janine Thomas(6), Jennifer Martin(6), Graeme J. Poston(5), Andrew P. Barbour(5), Halfdan Sørbye(4), Peter M. Schlag(4), John Primrose(4), Michael Findlay(4), Michael Poulsen(4)